Login to Your Account



Pharma: Other News To Note


Friday, September 28, 2012
• Forest Laboratories Inc., of New York, and Pierre Fabre Laboratories, of Castres, France, said Forest submitted a new drug application for levomilnacipran, a serotonin norephinephrine reuptake inhibitor, for the treatment of major depressive disorder in adults.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription